ABBN.SW: $86.18 ▲ 0.08 (0.09%)ASML.AS: $1,563.80 ▲ 3.00 (0.19%)ENR.DE: $160.06 ▼ -2.44 (-1.50%)GLEN.L: $535.10 ▼ -0.20 (-0.04%)IFX.DE: $81.12 ▲ 0.56 (0.70%)NOKIA.HE: $12.20 ▲ 0.20 (1.67%)RIO.L: $7,279.00 ▲ 15.00 (0.21%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

Blue Water Vaccines, Inc.

BWV - NASDAQ

Identifiants & Marche

Ticker BWV
ISIN US09610B1089
CIK 0001782107
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Blue Water Vaccines, Inc., a biotechnology company, engages in the research and development of vaccines to prevent infectious diseases worldwide. The company's lead vaccine programs that are under preclinical development include BWV-101, an influenza vaccine; and BWV-102, a H1 pre-pandemic vaccine. It also has other pipeline under preclinical development comprising BWV-201, a streptococcus pneumoniae induced acute otitis media vaccine program; BWV-301, a norovirus-rotavirus vaccine program; and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, Ohio.